The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries - 08/09/20
, Devon E. McMahon, BA a, Jules B. Lipoff, MD c, Misha Rosenbach, MD c, Carrie Kovarik, MD c, Seemal R. Desai, MD d, e, Joanna Harp, MD f, Junko Takeshita, MD, PhD, MSCE c, Lars E. French, MD g, h, Henry W. Lim, MD i, Bruce H. Thiers, MD j, George J. Hruza, MD, MBA k, Lindy P. Fox, MD l
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Coronavirus disease 2019 (COVID-19) has associated cutaneous manifestations.
Objective |
To characterize the diversity of cutaneous manifestations of COVID-19 and facilitate understanding of the underlying pathophysiology.
Methods |
Case series from an international registry from the American Academy of Dermatology and International League of Dermatological Societies.
Results |
The registry collected 716 cases of new-onset dermatologic symptoms in patients with confirmed/suspected COVID-19. Of the 171 patients in the registry with laboratory-confirmed COVID-19, the most common morphologies were morbilliform (22%), pernio-like (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulosquamous (9.9%), and retiform purpura (6.4%). Pernio-like lesions were common in patients with mild disease, whereas retiform purpura presented exclusively in ill, hospitalized patients.
Limitations |
We cannot estimate incidence or prevalence. Confirmation bias is possible.
Conclusions |
This study highlights the array of cutaneous manifestations associated with COVID-19. Many morphologies were nonspecific, whereas others may provide insight into potential immune or inflammatory pathways in COVID-19 pathophysiology.
Le texte complet de cet article est disponible en PDF.Key words : COVID-19, COVID toes, dermatology, global health, macular erythema, morbilliform, pernio, public health, registry, retiform purpura, SARS-CoV-2, urticarial, vesicular
Abbreviations used : AAD, IQR, PCR, SARS-CoV-2
Plan
| Funding sources: None. |
|
| Disclosure: Drs Freeman, Lipoff, Rosenbach, Kovarik, Desai, Takeshita, Thiers, Hruza, and Fox are part of the American Academy of Dermatology (AAD) COVID-19 Ad Hoc Task Force. Dr French is president and Dr Lim is a board member of the International League of Dermatological Societies. Dr Thiers is the president of the AAD. Dr Hruza is immediate past president of the AAD. Author McMahon and Dr Harp have no conflicts of interest to declare. |
|
| IRB approval status: The registry was reviewed by the Partners Healthcare (Massachusetts General Hospital) IRB and was determined to not meet the definition of human subjects research. |
|
| Reprints not available from the authors. |
Vol 83 - N° 4
P. 1118-1129 - octobre 2020 Retour au numéro
Article précédent
- Forehead location and large segmental pattern of facial port-wine stains predict risk of Sturge-Weber syndrome
- Markus D. Boos, Xiuhua L. Bozarth, Robert Sidbury, Andrew B. Cooper, Francisco Perez, Connie Chon, Gabrielle Paras, Catherine Amlie-Lefond
- Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
- Samantha R. Ellis, Aren T. Vierra, Jillian W. Millsop, Mario E. Lacouture, Maija Kiuru
Bienvenue sur EM-consulte, la référence des professionnels de santé.